Acepodia (6976.TWO) Stock Price

Acepodia Price

CLOSED
9.20
​
Market closed

Revenue at Acepodia has contracted by 89.4% per year over the past 2 years to 185,000.00 TWD. For Acepodia, the net margin of -407,784.3% is down versus -4,925.7% a few years ago.

Acepodia stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acepodia business model & stock analysis

Acepodia Inc generates revenue through the development and commercialization of innovative anti-cancer drug platforms. The company's primary products include the Gamma delta 2T cell platform featuring ACE1831 for lymphoma treatment targeting CD20, ACE2016 for EGFR+ solid tumors like lung cancer, and ACE1708 for PDL1-targeted solid tumor therapy. Additionally, the off-the-shelf natural killer (oNK) cell platform offers ACE1702 targeting HER2+ solid tumors such as breast cancer. These products are developed using proprietary technologies including antibody-cell conjugation (ACC), Gamma delta 2T cell screening and amplification, oNK cell culture, and specialized freezing and thawing techniques for cell drug preparations. The company focuses on treating specific cancer types through targeted antibody-linked therapies, with products designed for lymphoma, lung cancer, and breast cancer applications. Acepodia Inc's target customers are healthcare providers and oncology treatment centers specializing in cancer care. The company's products are positioned for specific cancer indications, with ACE1831 targeting CD20-positive lymphoma, ACE2016 targeting EGFR-positive solid tumors, and ACE1702 targeting HER2-positive breast cancer. The firm's technology enables the development of off-the-shelf cell therapies, reducing treatment preparation time for medical institutions. By focusing on antibody-linked cell therapies for specific cancer types, Acepodia Inc serves the biotechnology sector's demand for precision oncology treatments. The company monetizes its research and development through the sale of these cell-based therapies to hospitals and specialized cancer treatment facilities. The Gamma delta 2T cell platform and oNK cell platform represent the core revenue streams, with each product targeting distinct cancer types and molecular targets. ACE1831, ACE2016, and ACE1708 are developed for lymphoma, lung cancer, and solid tumors respectively, while ACE1702 is specifically designed for breast cancer treatment. These products are developed using Acepodia's proprietary antibody-cell conjugation and cell culture technologies, creating a differentiated product portfolio in the oncology drug market.

Frequently asked questions about Acepodia

Converted at the current exchange rate, the Acepodia share trades at 0.25 EUR (9.20 TWD).

The revenue cannot currently be calculated for Acepodia.

The profit cannot currently be calculated for Acepodia.

The P/E ratio cannot be calculated for Acepodia at the moment.

The P/S cannot be calculated for Acepodia currently.

The Eulerpool Quality Score for Acepodia is 2/10.

The ISIN of Acepodia is KYG0073G1091. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Acepodia is 6976.TWO. The ticker symbol is used to trade Acepodia shares on the stock exchange.

Fair ValueTerminal
8.37 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website acepodia.com
Country
Taiwan
Currency
TWD
Initial public offering
Aug 8, 2023
ISIN
KYG0073G1091
Cusip
G0073G109
Market capitalization
5.36 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
0.99
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-13.92 %
Last updated Nov 22, 2026, 3:43 AM

Acepodia Peer Group

Acepodia FIGI

6976:TT (Taipei Stock Exchange) · BBG01HQ02G40

All fundamentals and in-depth analysis of Acepodia

Our stock analysis for Acepodia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acepodia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.